Canine Nasal Tumors Study Guide

Overview and Clinical Importance

Nasal tumors represent approximately 1-2% of all canine neoplasms but account for 60-80% of all respiratory tract tumors in dogs. These tumors are predominantly malignant (approximately 80%) and are characterized by local invasiveness with relatively low metastatic rates at initial presentation. Understanding the clinical presentation, diagnostic approach, and treatment options is essential for the NAVLE examination.

The prognosis for untreated canine nasal tumors is poor, with a median survival time of approximately 95 days. However, with appropriate treatment, particularly radiation therapy, survival times can be significantly extended to 12-19 months or longer.

Epidemiology and Risk Factors

Signalment

Age: Median age at diagnosis is 10 years (range 2-16 years). Dogs with nasal sarcomas may present at an earlier age.

Sex: Slight male predisposition has been reported in some studies, though this remains debatable.

Breed: Medium to large breed dogs are more commonly affected. Dolichocephalic and mesocephalic breeds are considered at increased risk due to greater nasal surface area and increased exposure to inhaled carcinogens.

Breeds at Increased Risk

Environmental Risk Factors

• Environmental tobacco smoke (ETS) - established risk factor for canine nasal tumors
• Urban environments - increased exposure to air pollutants
• Indoor fossil fuel combustion products - coal or kerosene heaters
• Flea sprays - correlated with increased incidence

Tumor Classification and Histopathology

Canine nasal tumors are histologically diverse, with carcinomas being more common than sarcomas. Understanding the relative frequencies and biological behavior of each tumor type is essential for NAVLE preparation.

Clinical Signs and Presentation

Clinical signs are typically progressive and initially unilateral but may become bilateral as the tumor grows. Mean duration of clinical signs before presentation is approximately 3 months.

Common Clinical Signs

Differential Diagnoses

• Fungal rhinitis (Aspergillosis) - depigmentation of nasal planum, bilateral profuse discharge, facial pain
• Bacterial rhinitis - purulent discharge, may respond to antibiotics temporarily
• Foreign body - acute onset, paroxysmal sneezing, facial agitation
• Coagulopathy/bleeding disorders - bilateral epistaxis, petechiae, ecchymoses elsewhere
• Dental disease - oronasal fistula, unilateral discharge
• Trauma

Diagnostic Approach

Minimum Database and Staging Workup

A complete staging workup is essential before treatment planning, even though metastatic rates at diagnosis are low (less than 10-12%).

• Complete Blood Count (CBC) - may show anemia secondary to chronic blood loss
• Serum biochemistry panel - assess organ function before anesthesia
• Urinalysis
• Coagulation profile - ESSENTIAL before biopsy (PT, APTT, buccal mucosal bleeding time)
• Thoracic radiographs (3 views) - evaluate for pulmonary metastasis
• Regional lymph node evaluation - aspiration cytology of mandibular/retropharyngeal lymph nodes

Diagnostic Imaging

Radiographic/CT Findings Consistent with Nasal Neoplasia

• Increased soft tissue opacity within nasal cavity (often unilateral initially)
• Loss of turbinate bone detail/destruction
• Bony lysis of nasal/maxillary bones
• Deviation or destruction of nasal septum
• Frontal sinus opacification (secondary or direct extension)
• Cribriform plate lysis (advanced disease)

Tissue Sampling and Biopsy Techniques

Important: Always perform imaging (ideally CT) BEFORE biopsy to guide sampling and assess disease extent. A coagulation profile must be performed before any biopsy procedure.

Staging Systems

Modified Adams Staging System (CT-Based)

The Modified Adams staging system is commonly used and has prognostic significance for radiation therapy outcomes.

Treatment Options

Radiation Therapy (Treatment of Choice)

Radiation therapy is the GOLD STANDARD treatment for canine nasal tumors. It provides the best local control and longest survival times compared to other treatment modalities.

Radiation Therapy Protocols

Radiation Therapy Side Effects

Acute Effects (during/shortly after RT):

• Oral mucositis
• Moist desquamation of skin in radiation field
• Rhinitis, halitosis
• Conjunctivitis

Late Effects (months to years post-RT):

• Keratoconjunctivitis sicca (KCS)
• Cataracts (if dose greater than 40 Gy to eyes)
• Permanent alopecia and coat color change
• Chronic rhinitis (common, usually manageable)
• Oronasal fistula (rare)

Other Treatment Modalities

Prognostic Factors